08:00 , Feb 5, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/ marker/ pathway Summary Licensing status Publication and contact information Cancer Prostate cancer PIM-1 (PIM1) In vitro and mouse studies identified a mAb against PIM1 that could potentially help treat...
07:00 , Oct 23, 2006 |  BC Week In Review  |  Company News

Prima BioMed, Macfarlane Burnet Institute for Medical Research and Public Health deal

Under a two-year deal, the institute granted PRR first rights to IP related to ex vivo cell therapies for cancer. The agreement is renewable for an additional two years. If PRR exercises its right to...
07:00 , Aug 29, 2005 |  BC Week In Review  |  Company News

Prima, Austin Research Institute deal

PRR completed its acquisition of the institute's share and option holdings in four PRR subsidiaries (see BioCentury, Aug.15). PRR now owns all shares of Oncomab Pty Ltd., Panvax Ltd., Cancer Vac Pty Ltd., and 92.5%...
07:00 , Aug 15, 2005 |  BC Week In Review  |  Company News

Prima BioMed, Austin Research Institute deal

PRR proposed to acquire the institute's share and option holdings in four PRR subsidiaries for 15 million shares. The deal would be valued at A$1.7 million ($1.3 million) based on PRR's close of A$0.12 on...
08:00 , Feb 22, 2000 |  BC Week In Review  |  Company News

Alexion, Austin Research Institute deal

The partners modified a 1998 licensing agreement by returning to Austin the right to commercialize products associated with Austin’s alpha1,3 galactosyltransferase patent to prevent hyperacute rejection in organ and pancreatic islet xenotransplantation. ALXN retains commercialization...
08:00 , Feb 10, 2000 |  BC Extra  |  Company News

Alexion research extension

ALXN will extend its collaboration with Austin Research Institute to develop and commercialize Austin's alpha1,3 galactosyltransferase and the jointly owned fucosyltransferase for use in cell and tissue xenotransplantation....
07:00 , Oct 19, 1998 |  BC Week In Review  |  Clinical News

Alexion regulatory update

The Austin Research Institute (Victoria, Australia) received U.S. Patent No. 5,821,117 covering the cloned pig gal transferase gene and engineered pig cells with the gene inactivated, which ALXN uses in its xenotransplantation program. ALXN is...
08:00 , Mar 2, 1998 |  BC Week In Review  |  Company News

The Austin Research Institute other research news

Austin researchers and colleagues published in Nature Biotechnology the use of peptides that mimic the carbohydrate-modified form of the MUC1 mucin tumor antigen to induce anti-tumor immunity in mice. The researchers suggested that non-self peptide...
07:00 , Apr 4, 1994 |  BC Week In Review  |  Company News

Alexion deal

Unigraft aims to create a universal donor library of replacement parts from porcine tissues that will not induce immune rejection. A carbohydrate marker, galactose alpha (1-3) galactose on the surface of pig cells is believed...